Boehringer Ingelheim signs £574m deal for Lupin’s MEK inhibitor compound

勃林格殷格翰与印度鲁宾制药签署逾7亿美元协议,获得MEK抑制剂化合物授权

2019-09-06 17:00:00 PHARMACEUTICAL

本文共1005个字,阅读需3分钟

Boehringer Ingelheim has signed a licensing, development and commercialisation deal worth more than $700m (£573.85m) with Indian pharma company Lupin for the latter’s MEK inhibitor compound LNP3794. The partnership between Boehringer Ingelheim and Lupin will develop LNP3794 as a potential targeted therapy for patients with difficult-to-treat cancers. The companies will develop the MEK inhibitor compound in combination with one of Boehringer Ingelheim’s KRAS inhibitors for the treatment of patients with gastrointestinal and lung cancers. The combination drug will target patients harbouring a wide range of oncogenic KRAS mutations. According to Boehringer Ingelheim, the combination of its KRAS inhibitors with MEK inhibitors resulted in increased anti-tumour activity, as per preclinical data. The German pharma company said that the increased anti-tumour activity is based on the complementary mechanisms of action of the compounds in keeping a check on KRAS-driven cancers. Furthermore, the MEK inhibitors developed by Lupin have shown pre-clinical activity as a single agent and also in combination. In a small subset of patients, the MEK inhibitors succeeded in showing early clinical benefit. Boehringer Ingelheim global cancer research head Norbert Kraut said: “The licensing of Lupin’s novel MEK inhibitor enables us to pair with our innovative KRAS inhibitors to develop new combination treatment concepts providing more effective and durable responses for patients with cancers driven by activated KRAS who currently have limited treatment options available. “We have developed comprehensive approaches to successfully tackle the oncogenic KRAS–RAF–MEK–ERK pathway from the ground up and this partnership is another key building block in our long-term strategy to bring novel treatments to patients in our quest to defeat intractable cancer types.” As per the terms of the agreement, the Indian pharma company will be paid $20m (£16.4m) upfront and potential additional payments based on defined clinical, regulatory and commercial milestones, which take the total deal value to more than $700m (£573.85m). In addition, Lupin will be eligible to get double-digit royalties on the sales of the product from the German pharma company. Lupin managing director Nilesh Gupta said: “Lupin’s MEK Inhibitor program successfully cleared early clinical stages, demonstrating our capabilities in delivering world class innovation. We are proud of the achievements of our team and the capabilities we have built which enable us to further our new drug discovery program.”
博林格殷格翰(Boehringer Ingelheim)已与印度制药公司罗苹(Lupin)签署了一项价值逾7亿美元(合5.738亿美元)的许可、开发和商业化协议,用于后者生产MEK抑制剂化合物LNP3794。 勃林格殷格翰(Boehringer Ingelheim)和鲁宾(Lupin)之间的合作关系将发展 LNP3794,作为一种潜在的靶向治疗对难以治疗的癌症患者。 这些公司将与勃林格殷格翰(Boehringer Ingelheim)的 KRAS 抑制剂之一联合开发 MEK 抑制剂,用于治疗胃肠道和肺癌患者。该联合药物将针对具有广泛致癌 KRAS 突变的患者。 根据勃林格殷格翰(Boehringer Ingelheim)的说法,其 KRAS 抑制剂与 MEK 抑制剂的结合导致抗肿瘤活性增加,根据临床前数据。这家德国制药公司说,增加的抗肿瘤活性是基于化合物的补充作用机制,以保持对 KRAS 驱动的癌症的检查。 此外,鲁宾(Lupin)开发的 MEK 抑制剂作为单一的药物和组合显示了临床前的活性。在一小部分患者中, MEK 抑制剂成功地显示了早期的临床益处。 勃林格殷格翰(Boehringer Ingelheim)全球癌症研究负责人 Norbert Kraut 表示:“鲁宾(Lupin)新的 MEK 抑制剂获得许可,使我们能够与我们创新的 KRAS 抑制剂配对,开发新的联合治疗概念,为激活 KRAS 驱动的癌症患者提供更有效和持久的治疗方案,这些患者目前的治疗选择有限。 “我们已经制定了全面的方法,从根本上成功地解决了致瘤性 KRAS-RAF-MEK-ERK 途径,这一合作关系是我们长期战略的另一个关键组成部分,我们的目标是为寻求战胜棘手癌症类型的患者提供新的治疗。” 根据协议条款,这家印度制药公司将根据规定的临床、监管和商业里程碑支付2000万美元(合1640万英镑)的预付款和潜在的额外付款,这些里程碑将使交易总价值超过7亿美元(合5.7385亿英镑)。 此外,鲁宾(Lupin)将有资格从德国制药公司获得两位数的专利使用费。 Lupin 董事总经理 Nilsh Gupta 表示:“鲁宾(Lupin)的 MEK 抑制剂项目成功地清除了早期临床阶段,展示了我们提供世界级创新的能力。我们为我们的团队取得的成就和我们建立的能力感到自豪,这些能力使我们能够进一步推进我们的新药发现计划。”

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文